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Allred scoring for ER reporting and it's impact in clearly distinguishing
ER negative from ER positive breast cancers
Asim Qureshi,1 Shahid Pervez2
Department of Pathology, Shaukat Khanum Cancer Hospital, Lahore,1 Department of Histopathology, Aga Khan University Hospital, Karachi.2
Abstract
Objective: To determine the scoring of Estrogen Receptor (ER) status in carcinoma breast by Allred method that
is essentially bimodal and to compare the results with a conventional scoring system.
Materials and Methods: A retrospective, comparative study carried out at Aga Khan University Hospital Section
of Histopathology over a period of 18 months i.e. Jan 2005 to June 2006. Anti ER antibody (clone D07) was used
for all IHC stains using envision detection system. ER stains of 860 consecutive breast cancer cases were
reviewed and rescored by both conventional and Allred method of ER scoring.
Results: Comparison of results showed that there was a substantial decrease in weak positive cases from 18%
to 5% by rescoring using Allred scoring system compared to conventional scoring. The data was analyzed using
chi square test.
Conclusion: The sensitivity and specificity of Allred method were calculated; Sensitivity of Allred method was
99.4% & Specificity of Allred method was 99.5% whereas sensitivity and specificity of conventional method was
88.0 % and 84 % respectively (JPMA 60:350; 2010).
Introduction
Estrogen receptor is a regulator of mammary epithelial
growth, proliferation and differentiation whose complex
cellular interactions are mediated by a magnitude of ligands,
cofactors and other stimuli.1
The use of immunohistochemistry (IHC) to asses the
estrogen receptor (ER) status of breast cancer in formalin
fixed and paraffin embedded sections is now a routine practice
worldwide.2 Although ER status as determined by IHC
analysis has been shown to be a prognostic factor for patients
with breast cancer, major aim of determining the ER receptor
status is to assess predictive response to hormonal therapy.3,4
Carcinoma of breast is the most common malignancy in
women in Karachi, Pakistan and various scoring systems for
ER and PR are being used at different centres.5 However in
spite of its widespread use, lack of standardized scoring and
standardization of threshold for ER positivity has raised
concerns that a subset of patients is being misclassified with
regard to their ER status. There has been particular concern
that weakly ER positive tumours may erroneously be
categorized as ER negative resulting in turn being denied
potentially beneficial anti estrogen therapy6 or vice versa.
It is because of the weak positive group, Allred scoring
system was introduced in various university hospitals in North
America to minimize the borderline cases and to put them into
either positive or negative groups. Allred scoring reduces the
borderline or weak positive groups remarkably.
It is clear that most important factors in ER IHC are
pre analytical which include fixation time, processing quality,
antigen retrieval, clone of antibody used and detection system.
In the post staining scenario, interpretation of staining in terms
of number of cells stained and intensity of staining become
important to conclude whether a particular slide is classified as
positive or negative. In the conventional scoring system
described by Mc Carthy and also adopted by us, slides were
scored negative, weak positive, intermediate positive and
strong positive. Current literature however suggests that
scoring of ER into weak, intermediate and strong positive is at
times misleading. This is based on experience that if pre
analytical factors are controlled, ER is either un- equivocally
positive or negative.
Materials and Methods
Study Population:
ER stains of 860 consecutive breast cancer cases over
an 18 month period (Jan 2005-june 2006) reported in the
section of histopathology, Aga Khan University hospital were
reviewed.  
ER Immunohistochemical Analysis:
IHC for ER was performed on formalin fixed paraffin
embedded tissue sections as part of the routine clinical
evaluation of these cases using anti-ER antibody (clone D07,
DAKO) by using Envision system for detection. A positive
control sample consisting of invasive breast cancer known to
express ER was included with each staining batch. Inbuilt
control i.e. normal breast tissue was evaluated for ER staining
wherever included with tumour. For negative control primary
antibody was replaced by normal buffer. Those cases where no
normal breast tissue was present an additional control on the
top end of the slide was applied.
Scoring for ER Immunostains:
(a) Conventional scoring: The
immunohistochemical localization of ER was scored in a
semi quantitative fashion incorporating both the intensity
and the distribution of specific staining as described by Mc
Carthy, Jr et al.4 The evaluations were recorded as
percentages of positively stained tumour cells in each of the
five intensity categories denoted as zero (no staining), 1+
(weak but detectable), 2+ (mildly distinct), 3+ (moderately
distinct) and 4+ (strong). For each tissue a value designated
as HSCORE was derived by summing up the percentages of
cells staining at each intensity multiplied by the weighted
intensity of staining. An HSCORE of less than 50 was
established as negative, between 51 to 100 as mild (weak
positive), 101 to 200 as moderate (intermediate positive),
while 200 and more as strong positive.4
(b) Allred scoring: In addition, we determined for
each case an Allred score which is semi quantitative system
that takes into consideration the proportion of positive cells
(scored on a scale of 0-5) and staining intensity (scored on a
scale of 0-3). The proportion and intensity were then summed
to produce total scores of 0 or 2 through 8. A score of 0 -2 was
regarded as negative while 3 - 8 as positive (Figure-1).3,4 Idea
conceived from original paper.4
Results
These 860 cases studied for ER immuno-stains
included core needle biopsies, lumpectomies, mastectomies
and wide local excision biopsy specimens. Of these, 767
(89%) cases were infiltrating ductal carcinomas, 60 (7%) were
infiltrating lobular carcinomas and 33 (4%) were minor
variants of breast cancer.                          
 The frequency distribution of ER
immunohistochemical results based on estimated percentage
of tumour cells by conventional methods showed  457 (53%)
to be completely negative, 251 (29%) were intermediate to
strong positive and 152 (18%) were weak positive (Figure-2).
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Figure-1: Diagramatic representation of Interpreation of Allred Score.
Figure-2: Comparison of ER results, conventional versus Allred.
 These cases were rescored according to Allred score
which showed 459 (53%) tumors to be completely negative
(SCORE 0), 356 (42%) to be intermediate to strong positive
(SCORE 5-8) and only 45 (5%) to be weak positive (SCORE
3-4) a reduction of 13% when compared to conventional
scoring (Figure-2).
Statistical Analysis:
Conventional scoring technique by visual inspection
(as explained earlier by McCarthy) was taken as gold standard
and results Allred were compared with that to calculate the
sensitivity and specificity with the help of 2 x 2 table.
Sensitivity of Allred method = 99.4%
Specificity of Allred method = 99.5%
Sensitivity of conventional score= 88 %
Specificity of conventional score= 84%.
Discussion
The results of ER immunostaining performed at our
laboratory by conventional method, clearly indicate that the
results were essentially trimodal with a very broad ER weakly
positive band. However rescoring done by Allred method has
markedly decreased the weakly positive band upgrading them
into ER intermediate to strong positive cases. This was further
strengthened by the high sensitivity and specificity values.
The results of our study are comparable to Najdi et al9 in
which 6000 breast cancer cases were evaluated by
immunohistochemical analysis. These authors found that most
tumours were either unequivocally ER positive or ER
negative and any discrepancy to this was attributed to pre
analytical factors like inadequate tissue fixation.10-12
Although the results of this study demonstrate that
weakly ER positive tumours are rare using the method
employed in our laboratory other studies have clearly shown
that there is considerable inter laboratory variation in the
identification of tumours with lower levels of ER
expression.13,14 It could therefore be argued that it might be
difficult to generalize the results of our study to other
institutions.15,16 Our results are a function of careful attention
to technical details of the assay, use of appropriate control
samples and a high index of suspicion when unexpected
results are encountered.17,18
Taken together the result of all this highlights the role
of pre-analytical factors and assay details in determining the
distribution of immunohistochemical results in any given
population. In our view, justification is difficult for the routine
use of quantifying the ER Immunihistochemical results in
clinical practice.
In current clinical practice once a case is considered to
be ER positive the degree of ER positivity has no impact on
recommendations for the use of hormonal therapy. The results
of this study demonstrate that weakly ER positive tumors are
rare using the Allred method compared to conventional
scoring methods.19,20 ER is viewed by clinicians as
dichotomous rather than a continuous variable when assessing
patient suitability for anti estrogen therapy. Use of Allred
scoring gives a very clear message to clinicians with regard to
ER positivity versus negativity.21,22 Weak positive staining
report in the conventional scoring in contrast give the message
of equivocality to the clinician with a potential risk of
deprivation of anti estrogen therapy or otherwise.23,24
Conclusion
Our data suggest that by using Allred scoring the ER
staining results will be essentially bimodal i.e. completely
negative or unequivocally positive. If pre analytical factors are
controlled there should be very few cases which are weak ER
positive and these should be considered as positive for
treatment purposes. ER negative should be reserved only for
those cases which show complete absence of staining.
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